Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.54 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 6/20 | 0.51 |
| ▸ | NPY1R | P25929 | 5/20 | 0.51 |
| ▸ | NPY2R | P49146 | 4/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974522 | 0.91 | VIPR1 (0.61) | VIPR2VIPR1NPY4RNPY1RNPY2R | |
| SCHEMBL30092917 | 0.90 | NPY4R (0.56) | F2NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30116708 | 0.90 | VIPR2 (0.60) | VIPR2VIPR1IL23R | |
| SCHEMBL30581292 | 0.89 | VIPR2 (0.52) | VIPR2VIPR1F2IL23R | |
| SCHEMBL30092922 | 0.89 | NPY4R (0.54) | VIPR2VIPR1F2NPY4RNPY1R | |
| SCHEMBL29596003 | 0.88 | F2 (0.43) | VIPR2VIPR1F2 | |
| SCHEMBL30150683 | 0.87 | VIPR2 (0.59) | VIPR2VIPR1NPY4RNPY1RNPY2R | |
| SCHEMBL31031604 | 0.87 | NPY4R (0.63) | VIPR2VIPR1NPY4RNPY1RNPY2R | |
| SCHEMBL29679828 | 0.86 | F2 (0.52) | VIPR2VIPR1F2IL23R | |
| SCHEMBL16509008 | 0.86 | IL23R (0.57) | VIPR2VIPR1NPY4RNPY1RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049109-A1 | NOVEL IMMUNOMODULATORY, NEUROMODULATORY, OSTEOGENIC, AND ANTI-OSTEOPOROTIC HKUOT-S2 PROTEIN THAT ENHANCES BONE FRACTURE REPAIRS AND SUPPRESSES OSTEOPOROSIS DEVELOPMENT | UNIV HONG KONG (HK) | 2026-02-19 | — | — | US | disclosed |
| CN-119677768-A | Novel immunomodulatory, neuromodulating, osteogenic and anti-osteoporosis HKUOT-S2 proteins for enhancing fracture repair and inhibiting the progression of osteoporosis | 香港大学 | 2025-03-21 | — | — | CN | disclosed |
| WO-2024032713-A1 | NOVEL IMMUNOMODULATORY, NEUROMODULATORY, OSTEOGENIC, AND ANTI-OSTEOPOROTIC HKUOT-S2 PROTEIN THAT ENHANCES BONE FRACTURE REPAIRS AND SUPPRESSES OSTEOPOROSIS DEVELOPMENT | THE UNIVERSITY OF HONG KONG (CN) | 2024-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049109-A1 | NOVEL IMMUNOMODULATORY, NEUROMODULATORY, OSTEOGENIC, AND ANTI-OSTEOPOROTIC HKUOT-S2 PROTEIN THAT ENHANCES BONE FRACTURE REPAIRS AND SUPPRESSES OSTEOPOROSIS DEVELOPMENT | SOST, IRF3, BMP2 | VIPR2 188/4885VIPR1 448/4885F2 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.